

Resource Summary Report

Generated by [dkNET](#) on Aug 1, 2026

PE/Cyanine7 anti-mouse CD3

RRID:AB_1732057

Type: Antibody

Proper Citation

BioLegend Cat# 100220, RRID:AB_1732057

Antibody Information

URL: http://antibodyregistry.org/AB_1732057

Proper Citation: BioLegend Cat# 100220, RRID:AB_1732057

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE/Cyanine7 anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_1732057

Vendor: BioLegend

Catalog Number: 100220

Alternative Catalog Numbers: 100219

Record Creation Time: 20250819T223144+0000

Record Last Update: 20250820T022848+0000

Ratings and Alerts

No rating or validation information has been found for PE/Cyanine7 anti-mouse CD3.

No alerts have been found for PE/Cyanine7 anti-mouse CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 66 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zitti B, et al. (2026) Positioning and reversible suppression of CCR7+ dendritic cells in perivascular tumor niches shape cancer immunity. *Immunity*, 59(1), 161.

Herbrich S, et al. (2026) TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors. *Cancer cell*, 44(1), 187.

Zhan W, et al. (2026) Cathepsin-D-mediated MHC class I degradation contributes to immune evasion in colorectal cancer. *Cell reports. Medicine*, 102534.

Huang F, et al. (2025) Bile acids activate cancer-associated fibroblasts and induce an immunosuppressive microenvironment in cholangiocarcinoma. *Cancer cell*, 43(8), 1460.

Sun P, et al. (2025) A fluorescent STING ligand sensor for high-throughput screening of compounds that can enhance tumor immunotherapy. *Cell reports methods*, 5(7), 101106.

Nahiyera M, et al. (2025) Sca-1 expression depicts pro-inflammatory murine neutrophils under steady-state and pathological conditions. *Cell reports*, 44(7), 115995.

Allman A, et al. (2025) Splenic fibroblasts control marginal zone B cell movement and function via two distinct Notch2-dependent regulatory programs. *Immunity*, 58(1), 143.

Stomper J, et al. (2025) Sex differences in DNMT3A-mutant clonal hematopoiesis and the effects of estrogen. *Cell reports*, 44(4), 115494.

Liu W, et al. (2025) An erythroid-biased FOShi hematopoietic multipotent progenitor subpopulation contributes to adaptation to chronic hypoxia. *Cell stem cell*, 32(6), 935.

Kim DH, et al. (2025) Treatment of IL-18-binding protein biologics suppresses fibrotic progression in metabolic dysfunction-associated steatohepatitis. *Cell reports. Medicine*, 6(4), 102047.

Wu S, et al. (2025) Selective apoptosis of tumor-associated platelets boosts the anti-metastatic potency of PD-1 blockade therapy. *Cell reports. Medicine*, 6(3), 101984.

Liu WH, et al. (2025) Overcoming NK-mediated rejection by anti-3rd-party central memory veto CD8 T cells through downregulation of DNAM-1 on alloreactive NK cells. *Cell reports*, 44(5), 115674.

Cheng JN, et al. (2025) Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts. *Cancer cell*, 43(6), 1093.

Stadler S, et al. (2025) Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood. *Cancer immunology research*, 13(4), 487.

Jiang X, et al. (2025) Spliceosome inhibition induces Z-RNA and ZBP1-driven cell death in small cell lung cancer. *Cell reports*, 44(10), 116384.

Song H, et al. (2025) Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy. *Cancer cell*, 43(3), 503.

Gomez AM, et al. (2025) Aberrant hypothalamic neuronal activity blunts glucocorticoid diurnal rhythms in murine breast cancer. *Neuron*.

Zhao HY, et al. (2025) An oral tricyclic STING agonist suppresses tumor growth through remodeling of the immune microenvironment. *Cell chemical biology*, 32(2), 280.

Martins C, et al. (2024) Tumor cell-intrinsic PD-1 promotes Merkel cell carcinoma growth by activating downstream mTOR-mitochondrial ROS signaling. *Science advances*, 10(3), eadi2012.

Luo Z, et al. (2024) Voluntary exercise sensitizes cancer immunotherapy via the collagen inhibition-orchestrated inflammatory tumor immune microenvironment. *Cell reports*, 43(9), 114697.